We provide proof of concept evidence that pretreatment with DHODH inhibitors can improve the efficacy of immune checkpoint blockade in a highly aggressive and ICB-refractory mouse melanoma model (Fig 5 and Fig S5). Here, DHODH is linked to melanoma.